Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study.
about
Adverse effects of antiretroviral therapy for HIV infectionHIV Infection in the Elderly: Arising ChallengesLipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006.Severe weight gain, lipodystrophy, dyslipidemia, and obstructive sleep apnea in a human immunodeficiency virus-infected patient following highly active antiretroviral therapy.Adherence to the Mediterranean diet is associated with a lower risk of body-shape changes in Croatian patients treated with combination antiretroviral therapy.Is HIV a model of accelerated or accentuated aging?Age and racial/ethnic differences in the prevalence of reported symptoms in human immunodeficiency virus-infected persons on antiretroviral therapy.Carotid artery thickness is associated with chronic use of highly active antiretroviral therapy in patients infected with human immunodeficiency virus: A 3.0 Tesla magnetic resonance imaging study.The effects of intermittent, CD4-guided antiretroviral therapy on body composition and metabolic parametersEvidence-Based Management of an Individual Living with HIVMitochondrial toxicity and HIV therapy.Trans-cellular introduction of HIV-1 protein Nef induces pathogenic response in Caenorhabditis elegans.HIV-associated lipodystrophy.Strategies for treating HIV-related lipodystrophy.Incidence and predictors of regimen-modification from first-line antiretroviral therapy in Thailand: a cohort studyTrizivir.Selected metabolic and morphologic complications associated with highly active antiretroviral therapy.HIV-associated lipodystrophy: impact of antiretroviral therapy.Evaluation and management of dyslipidemia in patients with HIV infection.High Molecular Weight (HMW): total adiponectin ratio is low in hiv-infected women receiving protease inhibitors.HIV Protease Inhibitors: Effect on the Opportunistic Protozoan Parasites.HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy.Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions.Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment.Antiretroviral therapies associated with lipoatrophy in HIV-infected womenChanging patterns in the neuropathogenesis of HIV during the HAART era.Fat distribution in women with HIV infection.Fat distribution in men with HIV infection.The study of fat redistribution and metabolic change in HIV infection (FRAM): methods, design, and sample characteristicsThe reassurance of experience.Serum paraoxonase-3 concentration in HIV-infected patients. Evidence for a protective role against oxidation.Pharmacologic therapy for HIV-associated lipodystrophy.The effect of Spirulina platensis versus soybean on insulin resistance in HIV-infected patients: a randomized pilot study.The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities.HIV revisited: the global impact of the HIV/AIDS epidemic.Using mathematical modeling and control to develop structured treatment interruption strategies for HIV infection.Lipodystrophy in Human Immunodeficiency Virus (HIV) Patients on Highly Active Antiretroviral Therapy (HAART).Atherosclerotic cardiovascular disease risk in the HAART-treated HIV-1 population.Cutaneous effects of highly active antiretroviral therapy in HIV-infected patients.Current perspectives on HIV-associated lipodystrophy syndrome.
P2860
Q24617882-5960FE10-9F1A-427D-A086-F4E06571160CQ28076000-F1D8537A-4D47-401D-95B8-CEBCF830FAA2Q31143771-B4E7E778-C736-42D3-98DD-807EBBE7B082Q33722450-57823C5E-500A-455B-AC4F-D3AC807AB44DQ33752752-5A2E4B88-E218-4752-A587-0012BCA9F24EQ33792651-D12EA20B-4BC6-4C41-95F6-9A5DEEF2B016Q33803909-F89305A3-6B08-4F1D-AB9B-32918EA09A77Q33816071-D3E5C781-3C6C-43E6-918B-4EE1CD293DB7Q33985842-7B2593D0-79DD-471D-A62D-15D5554B22FFQ34019567-42FCF595-46CC-4843-8F1E-9155B46B4CEBQ34279271-F95637C8-C1FE-48AB-9B8E-1C51B86E795DQ34403732-C092FE8C-BE26-4B66-9BF8-7A98CB28A662Q34459421-D91A9BD4-9AB1-4107-998C-CC6B88EE6EDDQ34481623-EAE69F0A-84CC-4E34-BC13-99184C5BD7EEQ34484483-73F05630-2EF8-47C5-93A9-1178E254235EQ34628638-330028FE-46FD-4940-A9CD-B5835606758EQ34631672-85A9B91F-DE48-44FC-ACFE-9431517A17EDQ34655845-2C3651B9-6562-475E-A01F-476E2EA32695Q34743413-9345D875-4D3B-429B-AE5C-F2A0B09BC1BDQ34901050-3E51A14A-078E-4DF0-A4FA-D043F6F2A831Q35012924-4C35D55A-2EFC-47CE-8D39-5EA6728529B3Q35035055-0FEB6632-7A66-41FB-A7BB-261D013ECAC5Q35088160-013BE4C8-C0E8-43E9-840E-D3DAEDD64A77Q35093189-04BDAEBC-87DF-48AA-83EA-815F426FC651Q35097650-BC6D80F4-4194-4692-827B-BAB7B4489AB3Q35126422-21566FEC-BABE-45B8-A734-B96EC7E79269Q35194384-424893BA-F180-408A-9765-0395F9743916Q35194387-4C74C45B-B88B-409C-ADD0-7B2F2145666EQ35206623-CA48A08C-23C6-4BE8-B3AC-03D0EE43DCA6Q35583703-8EB2A9D3-D342-4CDD-8937-44B5391AC753Q35625941-D7668EAB-B6C8-48CE-83A7-45038D7D0E67Q35644854-2CF21623-4EA6-45DD-B879-42C3E5DFC36AQ35671049-5BE21F51-925A-4B5F-8679-C02A78582D82Q35676408-95A2B59E-993A-4D35-A6AF-72A6A9056A48Q35767480-F5009806-8C98-463B-88F9-FF158B5EA452Q36026242-1BA717FD-9BB6-4416-BDDB-CE3D4E474A16Q36068146-195D0C6C-F019-4CE8-9884-3328A617F2EEQ36070094-88BC7A07-DE06-4EA4-9EBE-9AC51FC4B46FQ36103159-87EC4A10-3EE9-4E98-8AEB-82AA1DE2C6F3Q36132967-DEC92E0F-62C5-403E-87BE-987FCD382A9B
P2860
Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Risk of lipodystrophy in HIV-1 ...... s: a prospective cohort study.
@ast
Risk of lipodystrophy in HIV-1 ...... s: a prospective cohort study.
@en
Risk of lipodystrophy in HIV-1 ...... s: a prospective cohort study.
@nl
type
label
Risk of lipodystrophy in HIV-1 ...... s: a prospective cohort study.
@ast
Risk of lipodystrophy in HIV-1 ...... s: a prospective cohort study.
@en
Risk of lipodystrophy in HIV-1 ...... s: a prospective cohort study.
@nl
prefLabel
Risk of lipodystrophy in HIV-1 ...... s: a prospective cohort study.
@ast
Risk of lipodystrophy in HIV-1 ...... s: a prospective cohort study.
@en
Risk of lipodystrophy in HIV-1 ...... s: a prospective cohort study.
@nl
P2093
P1433
P1476
Risk of lipodystrophy in HIV-1 ...... s: a prospective cohort study.
@en
P2093
A Phillips
E Martinez
J B Pérez-Cuevas
J L Blanco
J M Gatell
J Mallolas
P304
P356
10.1016/S0140-6736(00)04056-3
P407
P577
2001-02-01T00:00:00Z